COVID 19: Is SARS-CoV-2 Contaminating Surgical Aerosols From Laparoscopy and Open Abdominal Surgery?
NCT ID: NCT04444687
Last Updated: 2022-05-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2020-08-31
2021-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Laparoscopy and COVID-19 Contamination
NCT04608383
The Impact of Long-term Pessary Use on Pelvic Organ Prolapse oìduring Covid-19 Pandemic in Patients Attending Surgery
NCT06234449
Outcomes on Abdominal Versus Vaginal Morcellation At Time of Hysterectomy
NCT04434066
Role of Blood Management in Perioperative Outcomes
NCT04475497
Major Pelvic Hemorrhage in Complex Surgery
NCT04264988
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Since Switzerland and the city of Basel in particular currently have a high prevalence for CoVID 19 it is likely that surgeons will encounter patients with proven or suspected infection in the near future that require open or laparoscopic emergency surgical procedures. This offers the opportunity to collect a reasonable number of samples and smears from the abdominal cavity and surgical aerosols from these patients in limited time to answer the urgent question whether surgical smoke and aerosols of the abdominal cavity from CoVID-19 patients are contagious or not.
Investigators consider the trial to be a risk category A according to art 7 (HRO). There is no risk for patients included in this trial since the treatment of the patients will not differ from standard care. There will be no extra tests performed and only routine data will be collected. Specimen from laparoscopic smoke filters which are a protection device for medical staff will be tested on SARS-CoV-2 contamination.
Primary Objective:
The primary objective of the study is to investigate the contamination of surgical smoke and aerosols with SARS-COV-2 virus particles using the viral genome as a marker during laparoscopic and open abdominal emergency procedures for patients with suspected or proven infection.
Secondary objectives are to:
* assess the viral load in the peritoneal cavity and fluid
* compare viral load of smoke and aerosols in laparoscopic and open procedures
* assess possible transmission to surgeons during their service
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SARS-CoV-2-positive 01
SARS-CoV-2-positive patient, no symptoms, low viral load in tracheal aspirate, RNAemia not detectable
Test for SARS-CoV-2
* As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)
* After intubation samples are acquired in the OR
1. tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)
2. blood sample (as part of standard operation procedures for CoVID-19 patients)
3. fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy
4. Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)
* Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR.
SARS-CoV-2-positive 02
SARS-CoV-2-positive patient, symptoms, high viral load in tracheal aspirate, RNAemia not detectable
Test for SARS-CoV-2
* As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)
* After intubation samples are acquired in the OR
1. tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)
2. blood sample (as part of standard operation procedures for CoVID-19 patients)
3. fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy
4. Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)
* Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR.
SARS-CoV-2-positive 03
SARS-CoV-2-positive patient, symptoms, high viral load in tracheal aspirate, RNAemia detectable
Test for SARS-CoV-2
* As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)
* After intubation samples are acquired in the OR
1. tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)
2. blood sample (as part of standard operation procedures for CoVID-19 patients)
3. fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy
4. Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)
* Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR.
Control
Control patients, SARS-CoV-2-negative
Test for SARS-CoV-2
* As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)
* After intubation samples are acquired in the OR
1. tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)
2. blood sample (as part of standard operation procedures for CoVID-19 patients)
3. fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy
4. Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)
* Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Test for SARS-CoV-2
* As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)
* After intubation samples are acquired in the OR
1. tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)
2. blood sample (as part of standard operation procedures for CoVID-19 patients)
3. fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy
4. Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)
* Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Proven or suspected (not ruled out) SARS-CoV-2 infection (at the time of surgery)
* Undergoing urgent or emergency laparoscopic or open abdominal surgery
* Able to provide informed general consent on further use of clinical data
Exclusion Criteria
* Unable to provide informed general consent \& no possibility of informed general consent by proxy
* Recent (\<24h) negative test for SARS-CoV-2
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Basel, Switzerland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marco von Strauss und Torney
Role: PRINCIPAL_INVESTIGATOR
Clarunis University Centre for Gastrointestinal and Liver Diseases
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
052020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.